AKT1 and B-cell chronic lymphocytic leukemia: Furthermore, miR-34a was also shown to target AXL, a receptor tyrosine kinase that activates PI3K/AKT signaling, and to be overexpressed in chronic lymphocytic leukemia (CLL) [56].